Data Readout

BioAtla's BA3182 tests durability as expansion-phase data near in H2 2026

The bispecific already showed a confirmed partial response past six months and manageable cytokine release; the expansion readout will test whether that holds across more patients.

By AppliedXLJuly 13, 2026Trial NCT05808634

Executive Summary

BioAtla is advancing an early-stage bispecific T-cell engager in adenocarcinoma toward additional data later this year, building on an interim signal that showed a durable response and contained toxicity in a small group of heavily pretreated patients.
The expansion-phase data will show whether the tumor-control pattern seen at higher doses generalizes beyond the single confirmed responder reported so far, and whether cytokine release stays manageable as more patients are dosed.
The trial's primary completion date has moved out by more than three years since the study was first posted, a shift the sponsor's own operational tracking flags as a high-severity delay pattern, even as enrollment guidance and status have stayed stable.
No other industry trial targets the same EpCAM-by-CD3 combination in this population, leaving the mechanism without a direct precedent to benchmark against and placing the burden of proof entirely on BioAtla's own data.

The catalyst

BioAtla said it expects additional readouts from the expansion portion of its Phase 1 study of BA3182 in patients with unresectable or metastatic adenocarcinoma later in 2026, following the dose-escalation data it presented at the European Society for Medical Oncology meeting in 2025. The trial, registered as NCT05808634, is evaluating dose limiting toxicity and maximum tolerated dose in Part 1 and confirmed overall response rate under RECIST v1.1 in Part 2. It has enrolled toward a target of 168 patients and remains in recruiting status. BioAtla+1

Probability of Success

Endpoint Met91%

Completes52%

Clinical Significance9%

Regulatory78%

The interim signal

In the data presented through the September 10, 2025 cutoff, BioAtla reported a confirmed partial response at the 0.6 mg dose that had continued for more than six months in a patient with intrahepatic cholangiocarcinoma, and said it observed prolonged tumor control with increasing BA3182 doses. Adverse events were described as transient and manageable, with only two cases of cytokine release syndrome reported across the dose-escalation cohort as of that cutoff. That is a single confirmed response reported publicly to date, not a powered efficacy readout; the expansion cohort now underway is designed to test whether the pattern holds across more patients. BioAtla

Timing and protocol history

The trial's primary completion date has moved twice since it was first posted: from February 2025 to June 2025 in August 2024, and then from June 2025 to September 2028 in September 2025. That cumulative delay is enough that BioAtla's own risk tracking flags a high-severity multi-year slip pattern on the completion date, even though the study's status, enrollment target of 168, and recruiting designation have not changed. The near-term data BioAtla is guiding to in the second half of 2026 are interim expansion-cohort readouts, not the trial's formal primary completion, which now sits more than two years out. NCT05808634

The competitive frame

No industry trial targeting the same EpCAM x CD3 combination appears in the competitive landscape, leaving BA3182 without a direct comparator on mechanism. The nearest trials identified in the broader adenocarcinoma landscape target unrelated pathways, including VEGFR, PD-1, PD-L1, and EGFR, none of which bears directly on a T-cell-engager mechanism. That isolation means the expansion data will be judged against BioAtla's own prior signal rather than against a validated benchmark for this target combination in tumors outside the blood system.

What the sponsor is balancing

BioAtla, Inc. (Nasdaq: BCAB) disclosed the BA3182 update alongside separate news that it had aligned with the FDA on a Phase 3 registrational design for a different asset, mecbotamab vedotin's successor program Oz-V, in second-line-or-later oropharyngeal squamous cell carcinoma, and that it was finalizing a strategic partnership transaction. BA3182 sits earlier in the pipeline than that registrational program, and its expansion-cohort data function as an early derisking signal for the platform rather than a standalone regulatory catalyst. BioAtla

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.